All about 2024 Saxenda lawsuit: Saxenda belongs to a class of medications called DPP-4 inhibitors. Exenatide and liraglutide belong to a class of medications referred to as GLP-1 receptor agonists. These two classes of medication, DPP-4 inhibitors, and GLP-1 receptor agonists are called incretin-based therapies because incretin hormones lower blood sugar by stimulating or sustaining the production of insulin. What all incretin drugs have in common is that they manipulate GLP-1 hormone levels in the body. The underlying problem with incretin drugs is that they are known to cause abnormal cell growth in the pancreas. Since incretin drugs first came on the market there has been concern that the effect of these drugs on the pancreas may cause pancreatic cancer. But, as we discuss below, this link has not been scientifically established, at least not yet. See additional information on Saxenda lawsuit.

Gastroparesis is a condition that affects the normal movement of the muscles in the stomach, causing delayed emptying of the stomach’s contents. It can lead to symptoms such as nausea, vomiting, bloating, and abdominal pain. While various factors can contribute to the development of gastroparesis, recent studies have suggested a potential link between the use of Saxenda and gastroparesis and there has been an increase in the number of reports of individuals who developed gastroparesis after taking Saxenda.

The study found that, compared to patients on Contrave, patients taking the two GLP-1 agonists, including Saxenda, had a 9.09 times greater risk of pancreatitis, 4.22 times greater risk of bowel obstruction, and a 3.67 times greater risk of gastroparesis, or stomach paralysis. Moreover, CNN recently reported that at least two people taking drugs in the same class as Saxenda, one taking Ozempic and the other taking Wegovy, have experienced more than just minor stomach issues; these individuals have been diagnosed with gastroparesis, or “paralyzed stomachs.”

A resident of Kentucky has initiated a lawsuit against Novo Nordisk A/S and its subsidiaries, accusing the company of failing to warn about the potential risk of permanent stomach paralysis caused by its weight loss medication, Saxenda (liraglutide). The plaintiff consumed Saxenda from March 2019 to April 2021 and is now experiencing gastroparesis, which has resulted in severe consequences such as persistent vomiting and abdominal pain, requiring multiple visits to the hospital. The lawsuit alleges that since the drug’s approval by the FDA in 2014, Novo Nordisk has promoted Saxenda as a weight loss solution without adequately disclosing the potential for gastrointestinal disorders, despite clinical trials indicating such risks.

The exact mechanism by which Saxenda may contribute to the development of gastroparesis is not yet fully understood. However, it is thought that the medication may affect the nerves and muscles in the stomach, leading to a disruption in gastric motility. This can result in the delayed emptying of food from the stomach, causing the symptoms associated with gastroparesis. It normally takes around six to eight hours for food to pass from the stomach to the small intestine. With gastroparesis, however. the digestion process is extended with the amount of extension differing from person to person. One study which was published in the Lancet Gastroenterology and Hepatology observed how liraglutide affected digestion. The participants in the study took either liraglutide or a placebo for five weeks and then ate a meal containing a radioactive tracer which allowed researchers to see how long the food stayed in their stomachs.

Saxenda and Persistent Vomiting – Some of the most serious and debilitating side effects of Saxenda is persistent vomiting along with gastroparesis. Gastroparesis is a condition that affects the normal movement of the muscles in the stomach, causing delayed emptying of the stomach’s contents. This can lead to symptoms such as nausea, vomiting, bloating, and abdominal pain. Recent studies have suggested a potential link between the use of Saxenda and gastroparesis. A study examining the risks of people taking GLP-1 agonists for weight loss, including Saxenda, found that patients taking these medications had a 3.67 times greater risk of developing gastroparesis compared to those taking a different weight loss medication, Contrave.

Is There a Cure for Gastroparesis? According to the Mayo Clinic, there is no known cure for gastroparesis, although withdrawal of the drug may bring an end to it. Gastroparesis can cause major complications in the body, like dehydration, malnutrition, and a decreased quality of life. Has Saxenda been Recalled? No, despite the increase in reported serious Saxenda side effects and the corresponding increase in Saxenda lawsuits, the FDA has not recalled Saxenda. Will I Suffer Withdrawal Symptoms if I Stop Taking Saxenda ? Saxenda is not an addictive or habit-forming medication, and therefore you will not get withdrawal symptoms when you finish your treatment. However, you could develop a pattern of binge eating, blood sugar spike and weight gain which can cause anxiety and other health problems. If you are thinking of stopping Saxenda treatment it is best to talk to you doctor prior to suddenly stopping.

In some cases, individuals taking Saxenda have reported experiencing suicidal thoughts or behaviors, as well as new or worsening depression and changes in mood or behavior. These mental health concerns are particularly alarming and should be addressed immediately by seeking professional help.

If you took Saxenda and developed gallbladder disease, Saxenda stomach paralysis, or any other serious Saxenda side effects, contact Timothy L. Miles, a Sazenda lawyer in Nashville, today. ?You may be eligible for a Saxenda Lawsuit ?and possibly may be entitled to substantial compensation. Discover extra info on

?Timothy L. Miles is a plaintiff’s lawyer in Nashville, Tennessee, and a nationally known top-rated class action and product liability lawyer who has been leading the fight to protect the rights of injured victims for over 20 years.

Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for injured victims, consumers, and shareholders, shaped precedent-setting decisions, and delivered real reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards.